Cytek (CTKB)
Builds Aurora spectral flow cytometers that profile 30-plus markers per sample on benchtop hardware.
Something off on this page? Send us feedback.
Makes spectral flow cytometers, led by the Aurora platform, that read each fluorochrome's full emission curve to profile 30 or more markers per sample. Instruments are sold alongside proprietary reagents, analysis software, and service contracts, with sales concentrated among pharmaceutical, biotech, and academic research customers.
Builds spectral flow cytometers that capture each fluorochrome's full emission curve instead of a single peak, letting labs run panels of 30 or more markers on benchtop hardware. The Aurora platform, introduced in 2017, anchors a lineup that now spans a lower-cost Northern Lights analyzer and a newer high-throughput Aurora Evo model.
A 2023 acquisition added imaging and conventional flow cytometry lines, broadening the hardware beyond the original spectral method. Instruments are sold alongside proprietary antibody reagents, unmixing and analysis software, and installation and maintenance services, so revenue continues through consumables and service contracts after each sale.
Most sales go to pharmaceutical, biotech, and contract-research customers, with the remainder in academic and government labs. Financial reporting treats the business as a single operating segment, split only between product and service revenue.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Morgan Stanley | Target | Target: $5.50 | Target: $5 |
| May 13, 2026 | Stephens | Target | Target: — | Target: $4.75 |
| May 12, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $6 | Target: $5.50 |
| Dec 1, 2025 | Morgan Stanley | Target | Target: — | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $262.0M · Total debt $26.5M · Total assets $446.9M · Shareholders' equity $322.0M
- Revenue
- $48.1M
- Operating income
- −$11.4M
- Net income
- −$12.2M
No dividends on record.
| Institutions | 63.58% | 82.64M shares | |
|---|---|---|---|
| 156 holders · as of Jun 30, 2026 | |||
| Insiders | 10.48% | 13.63M shares | |
| 13 holders · as of Aug 20, 2026 | |||
| Other | 25.94% | 33.72M shares | |
| remainder | |||
129.98M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.37% | 9.58M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 7.18% | 9.34M | as of Jun 30, 2026 |
of 5 PagesInsider | 6.17% | 8.02M | filed Feb 14, 2022 |
Boston PartnersInstitution | 5.89% | 7.66M | as of Jun 30, 2026 |
HHLR Advisors, Ltd.Institution | 5.12% | 6.66M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- BD
Global #1 flow cytometry leader with deep clinical and research installed base
- Danaher
Beckman Coulter's CytoFLEX / DxFLEX / MoFlo hold the #2 global position
- Sony (ADR)
ID7000 spectral analyzer, Aurora's closest native full-spectrum rival
- Thermo Fisher Scientific
Attune acoustic-focusing cytometers and Invitrogen reagents overlap FSP
- Bio-Rad Laboratories
ZE5 flow cytometer and StarBright dye rival, plus a 2023 reagent-supply partner
- Agilent Technologies
NovoCyte benchtop analyzers undercut entry-level spectral flow tier
- Standard BioTools
CyTOF mass cytometry — adjacent 40+ parameter alternative to spectral flow
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cytek | $5.67 | +7.29% | $681.9M | — | — | 3.3 | +5.6% |
| BD | $183.47 | +1.53% | $49.79B | 54.4 | 13.9 | 2.4 | −9.6% |
| Danaher | $221.42 | +2.59% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Sony (ADR) | $23.44 | −0.66% | $138.53B | — | 27.4 | 1.7 | +0.3% |
| Thermo Fisher Scientific | $658.97 | +0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Bio-Rad Laboratories | $381.57 | +1.12% | $10.16B | 45.7 | 37.0 | 3.9 | −0.1% |
| Agilent Technologies | $166.60 | +2.87% | $45.75B | 31.9 | 25.4 | 6.2 | +8.1% |
| Standard BioTools | $0.7504 | +1.15% | $290.4M | — | — | 3.4 | −7.6% |
| Median | 38.3 | 25.3 | 3.9 | +0.3% |